SOUTH JORDAN, Utah, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that Merit Chairman and CEO, Fred Lampropoulos, is scheduled to present at the J.P. Morgan 42nd Annual Healthcare Conference on January 8, 2024, at 4:30pm PT. A live audio webcast of the conference presentation will be available on the investor section of the Merit Medical website www.merit.com.
“Merit is honored to be amongst this remarkable group of companies represented at the conference,” said Mr. Lampropoulos. “We are excited to share with this distinguished audience our continuing mission of product innovation to improve patients’ lives.”
ABOUT MERIT MEDICAL
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 700 individuals. Merit employs approximately 7,100 people worldwide.
TRADEMARKS
Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.
CONTACTS
PR/Media Inquiries
Sarah Comstock
Merit Medical
+1-801-432-2864 | This email address is being protected from spambots. You need JavaScript enabled to view it.
INVESTOR INQUIRIES
Mike Piccinino, CFA, IRC
Westwicke - ICR
+1-443-213-0509 | This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$90.89 |
| Daily Change: | 0.32 0.35 |
| Daily Volume: | 619,280 |
| Market Cap: | US$5.300B |
April 09, 2025 March 27, 2025 March 25, 2025 March 10, 2025 February 25, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
